Overriding imatinib resistance with a novel ABL kinase inhibitor

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Imatinib resistance in chronic myeloid leukemia (CML) is primarily driven by BCR-ABL kinase domain point mutations.
• These mutations alter drug binding, leading to treatment failure in CML patients.
• Understanding resistance mechanisms is crucial for developing next-generation therapies.

Purpose of the Study:

• To evaluate the efficacy of BMS-354825, a novel ABL kinase inhibitor, against imatinib-resistant BCR-ABL mutations in CML.
• To assess the therapeutic potential of BMS-354825 in preclinical models of BCR-ABL-driven leukemia.

Main Methods:

• Utilized crystallographic studies to predict inhibitor binding to resistant mutants.
• Tested BMS-354825's activity against 15 imatinib-resistant BCR-ABL mutants in vitro.
• Evaluated BMS-354825's efficacy in a mouse model of BCR-ABL-driven disease and in patient-derived bone marrow progenitor cells.

Main Results:

• BMS-354825 demonstrated retained activity against 14 out of 15 imatinib-resistant BCR-ABL mutants.
• The inhibitor significantly prolonged survival in mice with BCR-ABL-driven leukemia.
• BMS-354825 inhibited proliferation of both imatinib-sensitive and imatinib-resistant CML progenitor cells.

Conclusions:

• BMS-354825 represents a potent second-generation ABL kinase inhibitor effective against a broad spectrum of BCR-ABL mutations, including those conferring imatinib resistance.
• Molecular insights into resistance mechanisms can effectively guide the development of superior targeted cancer therapies.
• BMS-354825 shows significant therapeutic potential for CML patients who have developed resistance to imatinib.